<< Researchers discover cells that protect the respiratory tract from developing an allergic response | SBA provision, antitrust exemption and FTC involvement need to be addressed in Senate, says PIA >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski

OriGene Technologies' over-expression lysates adopted for Human Protein Atlas project

Published on November 10, 2009 at 4:18 AM · No Comments

OriGene Technologies, Inc. today announced Royal Institute of Technology in Sweden has adopted its VERIFY Tagged Antigen(TM) (Over-expression Lysates) in the Human Protein Atlas program. This program is funded by the Knut and Alice Wallenberg Foundation and is set up to explore the human proteome systematically using Antibody-Based Proteomics. "Generating high quality mono-specific antibodies in a high throughput manner is critical for the success of the program," commented Prof Mathias Uhlen, Program Director. "In a pilot testing using OriGene's over-expression cell lysates as Western blot positive controls, we were able to increase antibody validation success rate from 30% to 80%. We are extremely happy with the results and have decided to adopt these lysates in the official Human Protein Atlas program." Dr. Wei-Wu He, CEO of OriGene Technologies, commented, "We are honored to team up with a world renowned researcher like Prof. Uhlen. OriGene has built the most comprehensive cDNA clone collection. These over-expression lysates are the beginning of a series of products aimed at antibody validation and biomarker discovery. We are committed to provide both products and technical resource required by the Human Protein Atlas project."

SOURCE OriGene Technologies, Inc.

Posted in: Medical Science News

Tags: , , , , , ,

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading